지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2009.12
- 수록면
- 25 - 31 (7page)
이용수
초록· 키워드
오류제보하기
Estrogens are steroid hormones that regulate growth, differentiation and function in a broad range of target tissues in the body and the exposure to estrogens is an important determinant for risk of breast cancer. The biologic effects of estrogens are mediated through estrogen receptor (ER) αand β. Endocrine therapies first used more than 100 years ago and progressed toward an understanding of antigestrgen action and successful clinical development of antiestrogen for the treatment of breast cancer. Endocrine therapies are the most effective treatment for breast cancer expressing ER but resistance remained major problem.
Endocrine therapy resistance is commonly associated with ER mutation, Aromatase mutation, loss of ER, pharmacogenetic change, change of coactivators and corepressors, and crosstalk between ER and growth factor pathways. Preclinical models demonstrate that growth factor receptor tyrosine kinase inhibitors can restore Tamoxifen resistance and delay acquired resistance to estrogen deprivation therapy. Several clinical trials have been reported the results about combined treatment of endocrine agents and target agents to overcome or delay endocrine resistance. The addition of trastuzumab to the aromatase inhibitor and tyrosine kinase inhibitor lapatinib to letrozole has significantly improved progression-free survival in ER-positive/HER2-positive metastatic breast cancer. Epidermal growth factor receptor (EGFR) inhibitor gefitinib combined with endocrine therapies demonstrated small benefit in ER-positive metastatic breast cancer. Target agents to downstream signal pathway, such as mammalian target of rapamycin (mTOR) inhibitor and farnesyltransferase inhibitors (FTIs), showed the possibility for combine aged to prevent endocrine resistance. We need to understand and evaluate various signaling elements from multiple networks that crosstalk with ER. Combined therapy with selected targeted agents remains a promising approach to enhancing the efficacy of current endocrine therapies for breast cancer.
Endocrine therapy resistance is commonly associated with ER mutation, Aromatase mutation, loss of ER, pharmacogenetic change, change of coactivators and corepressors, and crosstalk between ER and growth factor pathways. Preclinical models demonstrate that growth factor receptor tyrosine kinase inhibitors can restore Tamoxifen resistance and delay acquired resistance to estrogen deprivation therapy. Several clinical trials have been reported the results about combined treatment of endocrine agents and target agents to overcome or delay endocrine resistance. The addition of trastuzumab to the aromatase inhibitor and tyrosine kinase inhibitor lapatinib to letrozole has significantly improved progression-free survival in ER-positive/HER2-positive metastatic breast cancer. Epidermal growth factor receptor (EGFR) inhibitor gefitinib combined with endocrine therapies demonstrated small benefit in ER-positive metastatic breast cancer. Target agents to downstream signal pathway, such as mammalian target of rapamycin (mTOR) inhibitor and farnesyltransferase inhibitors (FTIs), showed the possibility for combine aged to prevent endocrine resistance. We need to understand and evaluate various signaling elements from multiple networks that crosstalk with ER. Combined therapy with selected targeted agents remains a promising approach to enhancing the efficacy of current endocrine therapies for breast cancer.
목차
서론
본론
결론
REFERENCES
Abstract
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Overcoming endocrine therapy resistance in breast cancer
대한임상종양학회 학술대회지
2009 .09
-
Endocrine therapy for metastatic breast cancer
대한외과학회 학술대회 초록집
2016 .11
-
Endocrine therapy
대한외과학회 학술대회 초록집
2016 .11
-
에스트로겐 수용체 ${\beta}$ 발현과 유방암 재발과의 관련성
영남의대학술지
2011 .01
-
Mechanism of endocrine therapy resistance : How to overcome?
대한외과학회 학술대회 초록집
2016 .11
-
젖샘(유선)발암과정에서 에스트로겐 수용체 발현
Laboratory Animal Research
2004 .12
-
PI3K and mTOR for Overcoming Endocrine Resistance in Breast Cancer
대한임상종양학회 학술대회지
2014 .03
-
4. Endocrine
대한외과학회 학술대회 초록집
2013 .11
-
Endocrine
대한외과학회 학술대회 초록집
2015 .11
-
Estrogen Receptor α Roles in Breast Cancer Chemoresistance
Asian Pacific journal of cancer prevention : APJCP
2013 .01
-
Endocrine Disruptors and Breast Cancer Risk - Time to Consider the Environment
Asian Pacific journal of cancer prevention : APJCP
2012 .01
-
What predicts better prognosis in elderly breast cancer patients?
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2020 .06
-
ASTRRA trial : The optimal endocrine therapy for premenopausal women with breast cancer
대한외과학회 학술대회 초록집
2015 .11
-
[Free Paper] The Implications of Hormone Receptors Status on Survival in Luminal A Subtype Breast Cancer Patients Received Endocrine Therapy : The Nationwide Korean Breast Cancer Society Registration Program
대한외과학회 학술대회 초록집
2011 .11
-
유방암 환자에서 원발암과 재발암의 호르몬 수용체 변화
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2013 .12
-
Recent Progress in HER2 Associated Breast Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Action mechanism of Antiestrogenicity of Ginkgo biloba extracts and its major components in human breast cancer cell
대한약학회 학술대회
2003 .01
-
Functions and physiological roles of two types of estrogen receptors, ERα and ERβ, identified by estrogen receptor knockout mouse
Laboratory Animal Research
2012 .06
-
Chemopreventive effect of Ginkgo biloba extract on breast cancer: Regulation of estrogen level
대한약학회 학술대회
2002 .01
-
Estrogen Receptor Alpha Gene Expression in Breast Cancer Tissues from the Iranian Population - a Pilot Study
Asian Pacific journal of cancer prevention : APJCP
2014 .01
이 논문의 저자 정보
이 논문과 함께 이용한 논문
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2014-513-001300413